Anastrozole Tablet
Product Images NDC 68071-1543

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 68071-1543). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 1543 9)

Label for Anastrozole 1 mg tablets by NuCare Pharmaceuticals, Inc., containing 90 tablets. The label includes the NDC 68071-1543-9 and product number R1484090. Instructions advise to see the manufacturer's label for ingredients and warnings to keep out of reach of children and store at controlled temperature 68-77°F. Manufacturer is Intas Pharmaceuticals Limited, India.*

FDA Label Image

Figure 1 (Anastrozole Fig1)

A Kaplan-Meier survival curve chart showing disease-free survival over 90 months for patients randomized to treatment with anastrozole or tamoxifen. The y-axis represents the proportion alive and disease-free, while the x-axis shows disease-free survival in months. Patient numbers at risk for each treatment group are listed below the x-axis.*

FDA Label Image

Figure 2 (Anastrozole Fig2)

A line graph depicting disease-free survival proportions over time in months for patients treated with anastrozole and tamoxifen. The x-axis represents disease-free survival in months, and the y-axis shows the proportion alive and disease-free. Two curves compare randomized treatments of anastrozole (dashed line) and tamoxifen (solid line), with patient numbers at risk displayed below the graph at multiple time points.*

FDA Label Image

Figure 3 (Anastrozole Fig3)

A Kaplan-Meier curve chart displaying the proportion of patients recurrence-free over time up to 120 months. The chart compares two treatments: Anastrozole and Tamoxifen, with lines depicting their respective survival rates. The x-axis shows time to event in months, and the y-axis indicates the proportion recurrence-free. Below the graph, the number of patients at risk at various time points is listed for both treatments.*

FDA Label Image

Figure 4 (Anastrozole Fig4)

A Kaplan-Meier survival curve comparing the proportion of patients remaining event-free over time in months for Anastrozole versus Tamoxifen treatment. The graph includes numbers of patients at risk at different time points up to 120 months follow-up.*

FDA Label Image

Figure 5 (Anastrozole Fig5)

A line graph comparing the time to progression (in months) of two randomized treatments: Anastrozole and Tamoxifen. The y-axis represents the proportion of patients not progressing, while the x-axis shows time in months. Lines indicate survival curves for each treatment group over approximately 32 months.*

FDA Label Image

Figure 6 (Anastrozole Fig6)

A survival plot chart comparing time to progression in months for two randomized treatments, Anastrozole and Tamoxifen. The graph shows the proportion not progressed over time with curves for each treatment, including a table of patients at risk at specified months below the x-axis.*

FDA Label Image

Chemical Structure For Anastrozole (Anastrozole Str)

Chemical structure diagram of Anastrozole, the active ingredient. The structure shows a triazole ring attached to a benzene ring substituted with nitrile and methyl groups, depicting the molecular framework of this oral tablet drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.